6.85
-0.36(-4.99%)
Currency In USD
| Previous Close | 7.21 |
| Open | 7.15 |
| Day High | 7.3 |
| Day Low | 6.8 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 6.2 |
| Volume | 21,331 |
| Average Volume | 216,790 |
| Market Cap | 3.99M |
| PE | 0 |
| EPS | -5,151.65 |
| Moving Average 50 Days | 28.41 |
| Moving Average 200 Days | 1,108.47 |
| Change | -0.36 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.02 as of May 09, 2025 at a share price of $6.85. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.06 as of May 09, 2025 at a share price of $6.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Welcomes Advocate Health as CLARITY Trial Site
GlobeNewswire Inc.
May 05, 2025 10:00 AM GMT
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to becom
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
GlobeNewswire Inc.
Apr 29, 2025 10:00 AM GMT
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo.
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
GlobeNewswire Inc.
Apr 23, 2025 10:00 AM GMT
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help